JP2017524734A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524734A5
JP2017524734A5 JP2017521031A JP2017521031A JP2017524734A5 JP 2017524734 A5 JP2017524734 A5 JP 2017524734A5 JP 2017521031 A JP2017521031 A JP 2017521031A JP 2017521031 A JP2017521031 A JP 2017521031A JP 2017524734 A5 JP2017524734 A5 JP 2017524734A5
Authority
JP
Japan
Prior art keywords
amino
methyl
carbonyl
thienyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017521031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524734A (ja
JP6603712B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/038712 external-priority patent/WO2016004136A1/en
Publication of JP2017524734A publication Critical patent/JP2017524734A/ja
Publication of JP2017524734A5 publication Critical patent/JP2017524734A5/ja
Application granted granted Critical
Publication of JP6603712B2 publication Critical patent/JP6603712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017521031A 2014-07-01 2015-06-30 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物 Active JP6603712B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462019756P 2014-07-01 2014-07-01
US62/019,756 2014-07-01
US201562185678P 2015-06-28 2015-06-28
US62/185,678 2015-06-28
PCT/US2015/038712 WO2016004136A1 (en) 2014-07-01 2015-06-30 Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019187426A Division JP2020023538A (ja) 2014-07-01 2019-10-11 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Publications (3)

Publication Number Publication Date
JP2017524734A JP2017524734A (ja) 2017-08-31
JP2017524734A5 true JP2017524734A5 (https=) 2019-07-11
JP6603712B2 JP6603712B2 (ja) 2019-11-06

Family

ID=55019950

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017521031A Active JP6603712B2 (ja) 2014-07-01 2015-06-30 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2019187426A Withdrawn JP2020023538A (ja) 2014-07-01 2019-10-11 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2021131914A Pending JP2021178869A (ja) 2014-07-01 2021-08-13 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2023191459A Withdrawn JP2024012558A (ja) 2014-07-01 2023-11-09 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019187426A Withdrawn JP2020023538A (ja) 2014-07-01 2019-10-11 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2021131914A Pending JP2021178869A (ja) 2014-07-01 2021-08-13 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2023191459A Withdrawn JP2024012558A (ja) 2014-07-01 2023-11-09 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Country Status (39)

Country Link
US (6) US9683003B2 (https=)
EP (3) EP3901159A1 (https=)
JP (4) JP6603712B2 (https=)
KR (1) KR102491125B1 (https=)
CN (1) CN106999479B (https=)
AU (1) AU2015284135B2 (https=)
BR (1) BR112016030787B1 (https=)
CA (1) CA2953132C (https=)
CL (1) CL2016003398A1 (https=)
CR (1) CR20170021A (https=)
CY (1) CY1122808T1 (https=)
DK (1) DK3164130T3 (https=)
DO (1) DOP2016000339A (https=)
EA (1) EA034119B1 (https=)
EC (1) ECSP17006751A (https=)
ES (1) ES2754359T3 (https=)
GE (2) GEP20197047B (https=)
HR (1) HRP20191979T1 (https=)
HU (1) HUE045748T2 (https=)
IL (1) IL249820B (https=)
LT (1) LT3164130T (https=)
ME (1) ME03574B (https=)
MX (1) MX376054B (https=)
MY (1) MY183649A (https=)
NZ (1) NZ728162A (https=)
PE (1) PE20170520A1 (https=)
PH (1) PH12016502595B1 (https=)
PL (1) PL3164130T3 (https=)
PT (1) PT3164130T (https=)
RS (1) RS59474B1 (https=)
SG (1) SG11201610476VA (https=)
SI (1) SI3164130T1 (https=)
SM (1) SMT201900600T1 (https=)
TN (1) TN2016000581A1 (https=)
TW (1) TWI680970B (https=)
UA (1) UA122963C2 (https=)
UY (1) UY36198A (https=)
WO (1) WO2016004136A1 (https=)
ZA (1) ZA201700386B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
JP2015524442A (ja) 2012-08-03 2015-08-24 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. Uba6のインドール置換ピロロピリミジニル阻害剤
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
US10465447B2 (en) 2015-03-12 2019-11-05 Baker Hughes, A Ge Company, Llc Cutting elements configured to mitigate diamond table failure, earth-boring tools including such cutting elements, and related methods
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
TN2019000087A1 (en) 2016-10-03 2020-07-15 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
TN2019000212A1 (en) 2017-02-27 2021-01-07 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
US10400517B2 (en) 2017-05-02 2019-09-03 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and related tools and methods
WO2019060536A1 (en) 2017-09-21 2019-03-28 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDEN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
US11059850B2 (en) 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues
WO2019180683A1 (en) 2018-03-23 2019-09-26 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
MX2021000349A (es) * 2018-07-09 2021-05-14 Takeda Pharmaceuticals Co Administracion de un inhibidor de la enzima activadora de sumo y anticuerpos anti-cd20.
US10570668B2 (en) 2018-07-27 2020-02-25 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and mitigate polycrystalline, superabrasive material failure earth-boring tools including such cutting elements, and related methods
CN109354569A (zh) * 2018-11-27 2019-02-19 常州大学 一种1,3-二溴-4-氟苯的制备方法
US20220133884A1 (en) * 2019-02-26 2022-05-05 Millennium Pharmaceuticals, Inc. Compounds useful as adjuvants
CA3128521A1 (en) 2019-02-27 2020-09-03 Millennium Pharmaceuticals, Inc. Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用prmt5抑制劑治療癌症之方法
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
CN112402608B (zh) * 2020-11-30 2021-09-07 深圳先进技术研究院 5-烷氧基吲哚-3-乙烯基喹啉盐作为靶向可迁移光敏剂的应用
WO2021203001A1 (en) * 2020-04-03 2021-10-07 Millennium Pharmaceuticals, Inc. Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme
AU2021271808A1 (en) * 2020-05-15 2023-01-05 Takeda Pharmaceutical Company Limited Administration of SUMO-activating enzyme inhibitor and anti-CD38 antibodies
MX2023009131A (es) 2021-02-05 2023-09-19 Baker Hughes Oilfield Operations Llc Elementos de corte para herramientas de perforación de tierra, y métodos para fabricar herramientas de perforación de tierra.
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
US11920409B2 (en) 2022-07-05 2024-03-05 Baker Hughes Oilfield Operations Llc Cutting elements, earth-boring tools including the cutting elements, and methods of forming the earth-boring tools
US20260035382A1 (en) * 2022-09-30 2026-02-05 Wigen Biomedicine Technology (shanghai) Co., Ltd. Compounds as sumo activating enzyme inhibitors
CN120112536A (zh) * 2022-11-11 2025-06-06 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
WO2024110863A1 (en) 2022-11-22 2024-05-30 Takeda Pharmaceutical Company Limited Process and intermediates for preparing ((1r,2s,4r)-4-((5-(4-((r)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate
CN117209449B (zh) * 2023-09-14 2025-11-28 上海毕得医药科技股份有限公司 一种2-(三氟甲基)噻唑类化合物的合成方法
NL2035852B1 (en) 2023-09-21 2025-03-28 Academisch Ziekenhuis Leiden Enhancement of t cell mediated therapies
CN119371416B (zh) * 2024-12-23 2025-05-30 上海达歌生物医药科技有限公司 一种通过氧杂环丁烷开环以构建4-取代异香豆素及其类似物的合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
JP2005524662A (ja) 2002-02-28 2005-08-18 ビオタ インコーポレーティッド ヌクレオシド5’−一リン酸模倣物およびこれらのプロドラッグ
JP2005525398A (ja) * 2002-04-10 2005-08-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2004009610A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
ES2285164T3 (es) 2002-09-04 2007-11-16 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
DE60313872T2 (de) 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
AU2003291024A1 (en) 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
US20070105890A1 (en) 2003-11-26 2007-05-10 Dainippon Sumitomo Pharma Co., Ltd Novel condensed imidazole derivative
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
PT1848718E (pt) 2005-02-04 2012-10-11 Millennium Pharm Inc Inibidores de enzimas de activação e1
CN101321759A (zh) 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
KR101450535B1 (ko) * 2006-02-02 2014-10-14 밀레니엄 파머슈티컬스 인코퍼레이티드 E1 활성화 효소의 억제제
EA201501088A1 (ru) * 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
TWI519508B (zh) 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
WO2009042013A1 (en) 2007-08-02 2009-04-02 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
ES2439009T3 (es) 2008-08-20 2014-01-21 Merck Sharp & Dohme Corp. Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
EP2326627A1 (en) 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SG175929A1 (en) 2009-05-14 2011-12-29 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
PE20130774A1 (es) 2010-07-29 2013-06-26 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de ampk y metodos para emplearlos
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
SG11201400102WA (en) 2011-08-24 2014-03-28 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
US9221809B2 (en) 2011-10-31 2015-12-29 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
CN105492429A (zh) * 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso

Similar Documents

Publication Publication Date Title
JP2017524734A5 (https=)
CN115605476B (zh) 取代的三环化合物
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
KR101750667B1 (ko) Syk 억제제
KR101903925B1 (ko) 헤테로아릴 화합물의 합성 및 정제 방법
DE60304718T2 (de) Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
JP5232841B2 (ja) N4−フェニルキナゾリン−4−アミン誘導体の製造方法およびその中間体
JP6306049B2 (ja) A2aアンタゴニスト特性を有するヘテロビシクロ−置換−[1,2,4]トリアゾロ[1,5−c]キナゾリン−5−アミン化合物
KR20210099611A (ko) 헤테로 방향족 유도체 조절제, 이의 제조방법 및 용도
AU2018243770A1 (en) Isoquinolines as inhibitors of HPK1
JP2022502424A5 (https=)
CN114539245A (zh) 含嘧啶并环类衍生物调节剂、其制备方法和应用
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
WO2015171527A1 (en) Pyrazolopyridine pyrazolopyrimidine and related compounds
AU2004210855A1 (en) Pyrazoles and methods of making and using the same
JP2005526029A (ja) 細胞増殖が関与する疾患を治療するためのキノリノン誘導体
CN107513068A (zh) 一种具有fgfr抑制活性的新型化合物及其制备和应用
KR20110039307A (ko) 이미다조피리딘-2-온 유도체
HRP20211483T1 (hr) Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka
JP2022502424A (ja) モノアシルグリセロールリパーゼ調節因子
AU2010334591C1 (en) Inhibitors of AKT activity
HU204273B (en) Process fo producing triazolo-benzo- and thieno-triazolo-diazepines and pharmaceutical compositions containing them
RU2019108717A (ru) Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
EP4288431A1 (en) Azabicyclic shp2 inhibitors
CA2723279A1 (en) 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses